Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research

Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database

(2015) Qian Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival

(2015) Satoshi Morita et al.   JNCI-Journal of the National Cancer Institute

Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival

(2015) Satoshi Morita et al.   JNCI-Journal of the National Cancer Institute

frailtypack: AnRPackage for the Analysis of Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or Parametrical Estimation

(2015) Virginie Rondeau et al.   Journal of Statistical Software

Rethinking Composite End Points in Clinical Trials

(2014) Joshua M. Stolker et al.   CIRCULATION

Bayesian semiparametric analysis of semicompeting risks data: investigating hospital readmission after a pancreatic cancer diagnosis

(2014) Kyu Ha Lee et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

A joint test for progression and survival with interval-censored data from a cancer clinical trial

(2014) Dianne M. Finkelstein et al.   STATISTICS IN MEDICINE

Identification and estimation of survivor average causal effects

(2014) Eric J. Tchetgen Tchetgen   STATISTICS IN MEDICINE

Use of composite endpoints in clinical trials

(2014) Abdul J. Sankoh et al.   STATISTICS IN MEDICINE

Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching

(2013) Yuanye Zhang et al.   LIFETIME DATA ANALYSIS

Progression-Free Survival: Meaningful or Simply Measurable?

(2012) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY

Statistical considerations when using a composite endpoint for comparing treatment groups

(2012) Guadalupe Gómez et al.   STATISTICS IN MEDICINE

Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study

(2011) D. Zeng et al.   BIOMETRIKA

Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?

(2011) Eitan Amir et al.   EUROPEAN JOURNAL OF CANCER

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

The value of progression-free survival to patients with advanced-stage cancer

(2011) Lesley J. Fallowfield et al.   Nature Reviews Clinical Oncology

Bayesian inference for an illness-death model for stroke with cognition as a latent time-dependent risk factor

(2011) Ardo van den Hout et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Frailties in multi-state models: Are they identifiable? Do we need them?

(2011) Hein Putter et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

(2010) Linda Wittkop et al.   Clinical Trials

Pitfalls of Using Composite Primary End Points in the Presence of Competing Risks

(2010) Loren K. Mell et al.   JOURNAL OF CLINICAL ONCOLOGY

A semi-competing risks model for data with interval-censoring and informative observation: An application to the MRC cognitive function and ageing study

(2010) Jessica K. Barrett et al.   STATISTICS IN MEDICINE

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

(2009) E. D. Saad et al.   ANNALS OF ONCOLOGY

Statistical Analysis of Illness-Death Processes and Semicompeting Risks Data

(2009) Jinfeng Xu et al.   BIOMETRICS

Issues in Using Progression-Free Survival When Evaluating Oncology Products

(2009) Thomas R. Fleming et al.   JOURNAL OF CLINICAL ONCOLOGY

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute

NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial

(2009) R. M. Goldberg et al.   ONCOLOGIST

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

(2008) Aloka Chakravarty et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Multi-state models for the analysis of time-to-event data

(2008) Luís Meira-Machado et al.   STATISTICAL METHODS IN MEDICAL RESEARCH